首页 | 本学科首页   官方微博 | 高级检索  
检索        

区域性灌注化疗时5-FU的血液和肝脏组织药物浓度分布特征
引用本文:郑惊雷,梁力建,胡文杰,沈顺利.区域性灌注化疗时5-FU的血液和肝脏组织药物浓度分布特征[J].南方医科大学学报,2008,28(5):823-827.
作者姓名:郑惊雷  梁力建  胡文杰  沈顺利
作者单位:中山大学附属第一医院肝胆外科,广东,广州,510080
摘    要:目的 研究经肝动脉和门静脉等不同途径区域灌注化疗时5-FU在大鼠血液和肝脏组织中的浓度分布和消除过程,为临床肝脏肿瘤化疗提供参考.方法 经颈静脉注射5-FU或分别经肝动脉及门静脉插管区域灌注,剂量为20 mg/kg体重.采用高效液相色谱法测定血浆及肝脏组织中5-FU的含量.进一步计算5-FU在肝脏和血浆中的药动学数据和穿透比率及治疗优势度.结果 外周静脉注射时,肝脏组织的药物峰浓度(Cmax)和药物时量曲线下面积(AUC)分别为13.79±4.56μg/g,342.20±108.20μg·min/g;血浆Cmax和AUC分别为36.85±5.96μg/ml,842.00?58.00μg·min/ml.肝动脉灌注5-FU时,肝脏组织药物Cmax和AUC分别为29.58±4.30μg/g,794.60±15.40 μg·min/g;血浆Cmax和AUC分别为24.39±4.63μg/ml,639.70?33.80μg·min/ml.门静脉灌注时,肝脏组织药物Cmax和AUC分别为2821±4.06μg/g,733.60±18.3μg·min/g;血浆Cmax和AUC分别为21.02±406μg/ml,529.80±111.50μg·min/ml.结论 与外周静脉注射全身化疗比较,区域性肝动脉或门静脉灌注化疗可显著提高肝脏组织中的药物浓度,同时减少化疗药物在外周血中的分布,可作为临床肝癌化疗的较好治疗措施.

关 键 词:5-氟尿嘧啶  肝脏肿瘤  区域化疗  浓度分布  区域性  门静脉灌注化疗  血液  肝脏组织  药物浓度  分布特征  infusion  local  tissue  liver  plasma  治疗措施  肝癌化疗  外周血  化疗药物  肝动脉灌注  比较  全身化疗  曲线下面积  时量
文章编号:1673-4254(2008)05-0823-05
修稿时间:2007年12月20

Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion
ZHENG Jing-lei,LIANG Li-jian,HU Wen-jie,SHEN Shun-li.Distribution of 5-FU in rat plasma and liver tissue after local 5-FU infusion[J].Journal of Southern Medical University,2008,28(5):823-827.
Authors:ZHENG Jing-lei  LIANG Li-jian  HU Wen-jie  SHEN Shun-li
Institution:Department of Hepatobiliary Surgeryìthe First Affiliated HospitalìSun Yat-Sen University, Guangzhou 510080, China.
Abstract:OBJECTIVE: To study the distribution of 5-FU in rat plasma and liver tissue following systemic or local 5-FU infusion. METHODS: 5-FU was administered at the dose of 20 mg/kg systemically via bolus injection through the jugular vein or locally via infusion through the hepatic artery and portal vein of the rats. High-performance liquid chromatography was used to measure 5-FU concentration in the plasma and liver tissue, and the pharmacokinetic parameters, penetration rate and therapeutic dominance of 5-FU were calculated. RESULTS: Systemic administration of 5-FU resulted in the peak 5-FU concentration (Cmax) and area under curve (AUC) in the liver tissue of 13.79-/+4.56 microg/g and 342.20-/+108.20 microg.min(-1).g(-1)g-1, with the plasma Cmax and AUC of 36.85-/+5.96 microg/g and 842.00-/+158.00 microg.min(-1).ml(-1), respectively. Local 5-FU administration through the hepatic artery resulted in Cmax and AUC in the liver tissue of 29.58-/+4.30 microg/g and 794.60-/+115.40 microg.min(-1).g(-1) and Cmax and AUC in the plasma of 24.39-/+4.63 microg/g and 639.70-/+133.80 microg.min(-1).ml(-1), respectively. After administration through the portal vein, the Cmax and AUC of 5-FU was 28.21-/+4.46 microg/g and 733.60-/+180.3 microg.min(-1).g(-1) in the liver tissue, and 21.02-/+4.06 microg/ml and 529.80-/+111.50 microg.min(-1).ml(-1) in the plasma, respectively. CONCLUSION: Compared with systemic venous bolus injection, administration through the hepatic artery and portal vein can significantly increase 5-FU concentration in the liver, and decrease its concentration in the peripheral blood.
Keywords:5-fluorouracil  hepatic neoplasms  regional chemotherapy  distribution  
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《南方医科大学学报》浏览原始摘要信息
点击此处可从《南方医科大学学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号